Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and safety of SARS-CoV-2 (COVID-19) vaccine in patients with hepatocellular carcinoma
TCTR20210525005Not yet recruiting
- Sponsor
- Chulalongkorn University
- Start
- Jun 2021
- Countries
- 1
01
Overview
Trial in coronavirus disease 2019 (COVID-19) and hepatocellular carcinoma (HCC), sponsored by Chulalongkorn University. Planned start Jun 2021; status: not yet recruiting.
02
Conditions
coronavirus disease 2019 (COVID-19)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on TCTR20210525005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210525005.